糖基因组用于增强液甲和利西诺普里尔在固定剂量组合中的肠道吸收
Aya R Elbasuony1, Abdelaziz E Abdelaziz2, Eman A Mazyed2
1Department of Pharmaceutical Technology, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt. Aya_elbasiony@pharm.kfs.edu.eg.
这项研究表明,甘基酶增强肠道吸收的化和lisinopril. 这些新型纳米载体改善了这些必不可少的心血管药物的输送.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药物运输 药物运输 药物运输
- 纳米技术纳米技术
背景情况:
- 甲酸和利西诺普里尔是常见的心血管药物,具有可变的肠道吸收.
- 固定的剂量组合旨在改善患者的遵守性,但可能会带来配方挑战.
- 了解药物相互作用和吸收限制对于优化治疗疗效至关重要.
研究的目的:
- 为了研究同时给药对甲和利西诺普里尔肠道吸收的影响.
- 探索糖基因组在增强两种药物的同时肠道吸收方面的潜力.
- 用于药物输送应用的糖基体的特征.
主要方法:
- 在位子肠道 perfusion 模型来评估药物膜的透性.
- 用基亚胺和lysinopril装载的甘基的制备和表征.
- 评估囊泡大小,药物捕获效率和稳定性 (泽塔潜力).
- 传输电子显微镜 (TEM) 用于囊泡形态分析.
主要成果:
- 甲 (第四类) 和利西诺普里尔 (第三类) 呈现不完全的肠道吸收.
- 药物的共同输注导致了利西诺普利的吸收减少.
- 同时封装在糖酶体中显著增强了两种药物的肠道吸收.
- 基于Tween的糖基基因体显示出更高的药物递送效率.
结论:
- 甘基体构成一个有前途的纳米载体系统,可以同时口服输送化亚和利西诺普里尔.
- 这种方法可以克服吸收限制,并提高这些抗高血压剂的生物可用性.
- 这些发现支持开发用于组合治疗的新型药物输送系统.
更多相关视频
08:44Preparation, Administration, and Assessment of In Vivo Tissue-Specific Cellular Uptake of Fluorescent Dye-Labeled Liposomes
Published on: July 30, 2020
10:16Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
Published on: February 8, 2017
相关概念视频
Antihypertensive Drugs: Thiazide-Class Diuretics
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Drugs for Treatment of Constipation-Predominant IBS
Pore Transport and Ion-Pair Transport
Pore transport, also known as convective transport, is a process where small molecules like urea, water, and sugars rapidly cross cell membranes as though there were channels or pores in the membrane. Although direct microscopic evidence is limited but the concept of pores or channels is widely accepted based on physiological evidence. Despite the lack of direct...
Antihypertensive Drugs: Potassium-Sparing Diuretics
